These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 29446283)

  • 1. Adjuvant Therapy in Resected Melanoma.
    Sladden M; Zagarella S; Bigby M
    N Engl J Med; 2018 Feb; 378(7):678. PubMed ID: 29446283
    [No Abstract]   [Full Text] [Related]  

  • 2. Adjuvant Therapy in Resected Melanoma.
    Weber J; Qureshi A; Ascierto PA
    N Engl J Med; 2018 Feb; 378(7):680. PubMed ID: 29446288
    [No Abstract]   [Full Text] [Related]  

  • 3. Adjuvant Therapy in Resected Melanoma.
    Maria ARJ; Viegas Dias C; Heleno B
    N Engl J Med; 2018 Feb; 378(7):679. PubMed ID: 29446287
    [No Abstract]   [Full Text] [Related]  

  • 4. Adjuvant Therapy in Resected Melanoma.
    Thomson N; Doerr R; Martin MG
    N Engl J Med; 2018 Feb; 378(7):678-9. PubMed ID: 29446285
    [No Abstract]   [Full Text] [Related]  

  • 5. Adjuvant Therapy in Resected Melanoma.
    Long GV; Hauschild A; Kirkwood JM
    N Engl J Med; 2018 Feb; 378(7):679-680. PubMed ID: 29443674
    [No Abstract]   [Full Text] [Related]  

  • 6. More on Adjuvant Therapy in Resected Melanoma.
    Faries MB; Stern S; Thompson JF
    N Engl J Med; 2018 Apr; 378(17):1656-1657. PubMed ID: 29694823
    [No Abstract]   [Full Text] [Related]  

  • 7. Adjuvant interferon for stage II melanoma.
    Haluska FG
    J Clin Oncol; 1998 Sep; 16(9):3205-6. PubMed ID: 9738597
    [No Abstract]   [Full Text] [Related]  

  • 8. Interferon adjuvant therapy of melanoma.
    Kirkwood JM; Wazer D; Rosenstein M
    Cancer; 1997 May; 79(9):1843-6. PubMed ID: 9129006
    [No Abstract]   [Full Text] [Related]  

  • 9. Duration of high-dose interferon alpha-2b regimen for resected high-risk melanoma.
    Agarwala SS; Gray RJ; Wong MK
    J Clin Oncol; 2009 Sep; 27(25):e82-3; author reply e84. PubMed ID: 19635995
    [No Abstract]   [Full Text] [Related]  

  • 10. [Adjuvant therapy of malignant melanoma].
    Franke W; Neumann NJ; Ruzicka T; Schulte KW
    Praxis (Bern 1994); 2001 Feb; 90(8):301-6. PubMed ID: 11256332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Update on adjuvant interferon therapy for high-risk melanoma.
    Agarwala SS; Kirkwood JM
    Oncology (Williston Park); 2002 Sep; 16(9):1177-87; discussion 1190-2, 1197. PubMed ID: 12380946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [High-dose interferon-alpha and adjuvant treatment of melanoma with poor prognosis: requiem for a drug marketing license?].
    Saiag P
    Ann Dermatol Venereol; 1999 Mar; 126(3):211-3. PubMed ID: 10394432
    [No Abstract]   [Full Text] [Related]  

  • 13. Adjuvant Therapy in High-Risk Stage III Cutaneous Melanoma.
    Kaufmann F; Goldinger SM
    Int J Radiat Oncol Biol Phys; 2017 May; 98(1):15-16. PubMed ID: 28586955
    [No Abstract]   [Full Text] [Related]  

  • 14. Malignant melanoma: non-metastatic.
    Crosby D; Crosby T; Mason M
    Clin Evid; 2002 Jun; (7):1519-29. PubMed ID: 12230768
    [No Abstract]   [Full Text] [Related]  

  • 15. Adjuvant high-dose interferon-alpha therapy for high-risk melanoma.
    Kirkwood JM; Tarhini AA
    Forum (Genova); 2003; 13(2):127-40; quiz 187-8. PubMed ID: 14732880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of cutaneous melanoma.
    Tsao H; Atkins MB; Sober AJ
    N Engl J Med; 2004 Sep; 351(10):998-1012. PubMed ID: 15342808
    [No Abstract]   [Full Text] [Related]  

  • 17. The adjuvant treatment of malignant melanoma.
    Reintgen D; Kirkwood J
    J Fla Med Assoc; 1997 Mar; 84(3):147-52. PubMed ID: 9143164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Malignant melanoma and adjuvant alpha interferon-2b for patients at high risk of relapse.
    Gale DM; Kiley KE
    Clin J Oncol Nurs; 1998 Jan; 2(1):5-10. PubMed ID: 9481250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long term follow up of the EORTC 18952 trial of adjuvant therapy in resected stage IIB-III cutaneous melanoma patients comparing intermediate doses of interferon-alpha-2b (IFN) with observation: Ulceration of primary is key determinant for IFN-sensitivity.
    Eggermont AM; Suciu S; Rutkowski P; Kruit WH; Punt CJ; Dummer R; Salès F; Keilholz U; de Schaetzen G; Testori A;
    Eur J Cancer; 2016 Mar; 55():111-21. PubMed ID: 26790144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Malignant melanoma. Less recurrence with interferon].
    MMW Fortschr Med; 2001 Feb; 143(5):55. PubMed ID: 11236804
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.